Retinal Detachment News and Research

RSS

Effective method to restore sight to patients with blinding diseases

Researchers at the University of California, Berkeley, have developed an easier and more effective method for inserting genes into eye cells that could greatly expand gene therapy to help restore sight to patients with blinding diseases ranging from inherited defects like retinitis pigmentosa to degenerative illnesses of old age, such as macular degeneration

13 Jun 2013

Study: Gene mutations are associated with severe form of nearsightedness

People have long taken for granted that glasses and contact lenses improve vision for nearsightedness, but the genetic factors behind the common condition have remained blurry. Now researchers at Duke Medicine are closer to clearing this up.

3 May 2013

Exposure to daylight helps protect children from myopia

Two new studies add to the growing evidence that spending time outdoors may help prevent or minimize nearsightedness in children. A study conducted in Taiwan, which is the first to use an educational policy as a public vision health intervention, finds that when children are required to spend recess time outdoors, their risk of nearsightedness is reduced.

2 May 2013

New study suggests that Ranibizumab can be potential prophylaxis for PVR

Proliferative vitreoretinopathy, or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life.

10 Apr 2013

Lund University researchers examine why people suffer vision loss in eye diseases

Using new technology and new approaches, researchers at Lund University in Sweden hope to be able to explain why people suffer vision loss in eye diseases such as retinal detachment and glaucoma.

4 Apr 2013

Pediatric blindness etiology varies around the globe

The causes and prevalence of blindness in children vary markedly by geography, presumably as a proxy for socioeconomic factors influencing prevention and treatment schemes, conclude the authors of a literature review.

15 Feb 2013

Second Sight Medical Products receives FDA approval for Argus II Retinal Prosthesis System

The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP).

14 Feb 2013

$Scientists discover 24 new genes that cause refractive errors and myopia$

Scientists discover 24 new genes that cause refractive errors and myopia

An international team of scientists led by King's College London has discovered 24 new genes that cause refractive errors and myopia (short-sightedness).

10 Feb 2013

Intravitreal ranibizumab shows little benefit after hemorrhage

Ranibizumab given intravitreally offers no clear benefit in the treatment of vitreous hemorrhage due to proliferative diabetic retinopathy, a randomized clinical trial indicates.

8 Feb 2013

NICE reject intravitreal implant for diabetic macular edema

The UK National Institute for Health and Clinical Excellence has not recommended a fluocinolone acetonide intravitreal implant for individuals with diabetic macular edema who do not respond to existing therapies.

5 Dec 2012

Eight days is magic number for macular reattachment

Individuals who have a macula-off rhegmatogenous retinal detachment for up to 8 days before being treated can expect continued improvement in their visual acuity for up to a year after reattachment surgery, show study results.

23 Nov 2012

One-day seminar to explore ophthalmic innovations

The newest ophthalmic innovations with market potential will be the focus of a one-day seminar in Seattle on May 3, 2013 that will connect scientists, venture capitalists, pharmaceutical representatives and others.

3 Nov 2012

Gas superior to air tamponade in lower quadrant vitrectomy

Gas and air are suitable tamponading agents for use during vitrectomy for rhegmatogenous retinal detachment, however air tamponade should only be used in cases that are restricted to the superior quadrants, study findings show.

30 Oct 2012

Universitat de València to use optical technology to prevent myopia

The Universitat de València will use optical technology in order to prevent myopia, which is considered the most common eye disease in the world. Until now, this technology was only used in astronomy to study images of the Universe.

26 Sep 2012

Weill Cornell to purchase innovative equipment to help detect and treat diabetic retinopathy

Weill Cornell Medical College's ophthalmology services for diabetic patients received a boost last month, courtesy of a grant from the New York City Council secured by Councilwoman Jessica Lappin.

21 Sep 2012

'ESASO Course Series’ for ophthalmologists

In the new book series 'ESASO Course Series', the essentials of the courses of the European School for Advanced Studies in Ophthalmology (ESASO) are made available to interested ophthalmologists, optometrists, technicians and residents all over the world.

23 Aug 2012

Number of blind persons decline in Germany

The numbers of people in Germany who are blind or visually impaired is going down. Robert P. Finger and his co-authors present their findings in the current edition of Deutsches -rzteblatt International.

21 Jul 2012

Risk factors defined for retinal detachment after cataract surgery

Study results spanning 22 years show that the risk for retinal detachment after undergoing phacoemulsification for cataracts has fallen dramatically, but that younger, and male patients are more at risk for this adverse outcome than their older, female peers.

20 Jul 2012

Oral fluoroquinolones increase risk of retinal detachment

In an analysis of a cohort that included nearly one million patients who had visited an ophthalmologist, patients who were taking oral fluoroquinolones had a higher risk of developing a retinal detachment, a serious eye condition, compared with nonusers, although the absolute risk was small, according to a study in the April 4 issue of JAMA.

4 Apr 2012

Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of data demonstrating the significant activity of aganirsen (GS-101, eye drops) in two important models of retinal neovascular disease, wet age-related macular degeneration (AMD) and ischemic retinopathy.

15 Feb 2012